NCT05702983View on ClinicalTrials.gov

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

April 11, 2023

Study Completion Date

April 24, 2023

Conditions
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions
DRUG

STSA-1002 subcutaneous injection

Subjects will receive a single low dose on day 1 following protocol requirements.

DRUG

STSA-1002 subcutaneous injection

Subjects will receive a single high dose on day 1 following protocol requirements.

Trial Locations (1)

66212

AltaSciences Clinical Kansas, Inc, Overland Park

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY